Group 1: Report Overview - Reported company: Nuotai Biotech [17] - Industry: Medical Services [2] - Research date: August 29, 2025 [17] - Company representatives: Chairman and President Tong Ziquan, Independent Director Liu Jian, Financial Controller Ding Wei, and Board Secretary Zhou Hua [17] Group 2: Research Institutions - Institutions participating in the research: Online investors [2] - Details of research institutions: The reception objects include online investors, and the types involve institution - related personnel and others [20] Group 3: Core Views - AI pharmaceutical cooperation: The company reached a comprehensive strategic cooperation with Shenshi Technology in the first half of the year, aiming to build a "Smart R & D - Precise Manufacturing - Ecological Empowerment" trinity value system, focusing on AI - empowered transformation of the biomedical industry [24] - Business cooperation plans: The BD team is actively expanding overseas big pharma business cooperation, and will disclose relevant progress according to regulations [25] - Contract liability changes: The decrease in contract liability compared to the beginning of the year is mainly due to the company's successive shipments during the period [26] - Revenue structure: The polypeptide API business accounts for a higher proportion of the company's current revenue [26] - Business partnerships: The company has cooperated with multiple leading generic drug companies on projects related to semaglutide and tirzepatide APIs and formulations, with overseas orders contributing more to revenue [26] - Product features: The company has established a solid - liquid fusion - based polypeptide large - scale production technology platform, with advantages in product yield, synthesis efficiency, quality, and cost [29] - Capacity expansion: The company will rely on its international BD team to expand into emerging markets to fill the newly - built capacity [29] Group 4: Other Key Points - Product inventory: The company's inventory includes raw materials, work - in - progress, and finished goods, and details can be found in the 2025 semi - annual report [28] - Market value management: The company's management will focus on the main business with superior resources to return good performance to investors and will apply for delisting the ST label after meeting the relevant conditions [27][29] - Regulatory response: The company will disclose the progress of the response to the CSRC's administrative penalty notice according to regulations [29]

Market Overview - The main funds in the Shanghai and Shenzhen markets experienced a net outflow of 69.47 billion yuan, with the Sci-Tech Innovation Board seeing a net outflow of 3.65 billion yuan [1] - A total of 251 stocks saw net inflows, while 333 stocks experienced net outflows [1] Sci-Tech Innovation Board Performance - On the Sci-Tech Innovation Board, 215 stocks rose, with one stock, Hangke Technology, hitting the daily limit, while 367 stocks fell [1] - The top three stocks with the highest net inflows were Yuntian Lifa (23.77 million yuan), Baijie Shenzhou (23.09 million yuan), and Daqian Energy (20.33 million yuan) [1] Continuous Fund Flow Analysis - There were 52 stocks with continuous net inflows for more than three trading days, with KHHW leading at nine consecutive days of inflow [1] - Conversely, 155 stocks had continuous net outflows, with ST Nuotai and Xuantai Pharmaceutical both experiencing 14 consecutive days of outflow [1] Top Fund Inflows - The top stocks by net inflow included: - Yuntian Lifa: 23.77 million yuan, 6.20% inflow rate, 6.38% increase [1] - Baijie Shenzhou: 23.09 million yuan, 9.56% inflow rate, 12.55% increase [1] - Daqian Energy: 20.33 million yuan, 16.32% inflow rate, 7.12% increase [1] Notable Outflows - The stock with the highest net outflow was SMIC, with a net outflow of 1.92 billion yuan and a 3.74% decrease [1] - Other significant outflows included Haiguang Information (864 million yuan) and Shijia Photon (382 million yuan) [1]

江苏诺泰澳赛诺生物制药股份有限公司 2025 年第一次临时股东会会议资料 二零二五年九月 2025 年第一次临时股东会会议资料目录 | 2025 年第一次临时股东会会议须知 | 2 | | --- | --- | | 2025 年第一次临时股东会会议议程 | 4 | | 议案一：关于变更会计师事务所的议案 | 6 | | 议案二：关于取消监事会、修订《公司章程》及其附件的议案 | 10 | | 议案三：关于制定、修订部分公司治理制度的议案 | 25 | | 附件一：江苏诺泰澳赛诺生物制药股份有限公司章程 | 26 | | 附件二：江苏诺泰澳赛诺生物制药股份有限公司股东会议事规则 | 77 | | 附件三：江苏诺泰澳赛诺生物制药股份有限公司董事会议事规则 | 91 | | 附件四：江苏诺泰澳赛诺生物制药股份有限公司累积投票制实施细则 | 100 | | 附件五：江苏诺泰澳赛诺生物制药股份有限公司关于防范控股股东、实际控制人及 | | | 其他关联方资金占用管理制度 104 | | | 附件六：江苏诺泰澳赛诺生物制药股份有限公司董事、高级管理人员薪酬管理制度 | | | 108 | | 证券代码：688076 证 ...

Group 1: Clinical Research Organization (CRO) Business Development - In the first half of 2025, the company's clinical research service revenue was approximately CNY 290 million, representing a 6.78% decrease compared to the same period last year [2] - The new clinical research service contract amount was CNY 752 million, indicating growth in market demand for clinical CRO services [2] - The company is expanding its clinical business team and expects clinical business prices to rise due to improved financing conditions [2] Group 2: Market Competition and Industry Trends - Many small CRO companies are facing operational difficulties, leading to layoffs and even closures, which is expected to increase industry concentration [3] - The company, being a well-established CRO, has strong performance capabilities and competitive advantages [3] Group 3: Research and Development Progress - The company has several self-developed projects, including a Class 1 innovative drug for chronic heart failure and various traditional Chinese medicine projects [4] - In the first half of 2025, new signed orders amounted to CNY 870 million, with over 50% from chemical drugs and over 20% from traditional Chinese medicine [4] Group 4: Future Business Plans and Financial Projections - The company plans to increase clinical staff in the second half of 2025, but not on a large scale [5] - The company aims to achieve revenue targets based on the 2024 stock incentive plan and expects to confirm approximately CNY 480 million in revenue in the second half of 2025 [7][11] - The gross margin for clinical CRO services is expected to increase due to higher quality demands and improved funding for innovative drug development [8] Group 5: Collaboration and Mergers - The company is open to mergers and acquisitions, particularly in the fields of vaccines and blood products, while focusing on its core business [12] - The company is actively seeking partners for its self-developed projects, including the "Runnor9591" project [6] Group 6: Regulatory and Operational Efficiency - The execution cycle for clinical projects varies, with significant improvements in efficiency and quality compared to previous years [10] - The company anticipates a decrease in expense ratios as revenue grows, with stable personnel levels [11]

关于江苏诺泰澳赛诺生物制药股份有限公司 2025 年半年度持续督导跟踪报告 根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板股票上市 规则》《上海证券交易所上市公司自律监管指引第 11 号——持续督导》等有关法 律法规的要求，南京证券股份有限公司（以下简称"南京证券"或"保荐机构"） 作为江苏诺泰澳赛诺生物制药股份有限公司（以下简称"诺泰生物""上市公司" 或"公司"）持续督导工作的保荐机构，负责诺泰生物上市后的持续督导工作， 并出具本持续督导跟踪报告。 南京证券股份有限公司 | 序号 | 工作内容 | 持续督导情况 | | --- | --- | --- | | 1 | 建立健全并有效执行持续督导工作 制度，并针对具体的持续督导工作 | 保荐机构已建立并有效执行了持续督导工作 | | | 制定相应的工作计划。 | 制度，并制定了相应的工作计划。 | | | 根据中国证监会相关规定，在持续 | | | | 督导工作开始前，与上市公司或相 | 保荐机构已与诺泰生物签订保荐协议，该协 | | 2 | 关当事人签署持续督导协议，明确 | 议明确了双方在持续督导期间的权利和义 | | | 双方在持续督导期间 ...

Group 1: Company Performance - CanSino reported a revenue of 382 million yuan for the first half of 2025, a year-on-year increase of 26%, with a net loss of 13.49 million yuan, narrowing by 94.02% compared to a loss of 225 million yuan in the same period last year [1] - Wantai Bio disclosed a revenue of 844 million yuan, a year-on-year decrease of 38.25%, resulting in a net loss of 144 million yuan, indicating a shift from profit to loss due to market adjustments and government procurement impacts [2] - Jimin Health reported a revenue of 366 million yuan, a year-on-year decline of 21.30%, with a net loss of 52.70 million yuan, compared to a profit of 25.44 million yuan in the previous year [3] - ST Noratech achieved a revenue of approximately 1.048 billion yuan, a year-on-year increase of 26.07%, with a net profit of about 310 million yuan, reflecting a growth of 36.49% [5] Group 2: Market Trends and Insights - The vaccine industry is facing challenges such as intensified competition and insufficient demand, leading to performance pressure on several companies, including CanSino and Zhifei Biological [2] - Jimin Health's stock experienced a significant increase of 53.78% over a short period, indicating potential market overreaction and speculative trading [3][4] - The demand for peptide raw materials, particularly GLP-1 related products, has driven ST Noratech's performance, highlighting a strong market for specific pharmaceutical segments [5] Group 3: Shareholder Actions - TBP 3Doctors (HK) Limited plans to reduce its stake in Sanbo Brain Science by up to 6.09 million shares, representing 3% of the total share capital, which may signal a lack of confidence in the company's future prospects [6]

Group 1 - The chemical pharmaceutical sector increased by 2.53% on August 25, with Shutaishen leading the gains [1] - The Shanghai Composite Index closed at 3883.56, up 1.51%, while the Shenzhen Component Index closed at 12441.07, up 2.26% [1] - Notable gainers in the chemical pharmaceutical sector included: - Buzoushen (300204) with a closing price of 61.00, up 16.17% and a trading volume of 445,500 shares [1] - Haichen Pharmaceutical (300584) with a closing price of 58.95, up 13.61% and a trading volume of 217,200 shares [1] - Changshan Pharmaceutical (300255) with a closing price of 53.25, up 12.84% and a trading volume of 683,900 shares [1] Group 2 - The chemical pharmaceutical sector experienced a net outflow of 426 million yuan from institutional investors, while retail investors saw a net inflow of 509 million yuan [2] - The top stocks by net inflow from retail investors included: - Anglikang (002940) with a net inflow of 163 million yuan, representing 22.87% of its trading volume [3] - Haichen Pharmaceutical (300584) with a net inflow of 132 million yuan, representing 10.90% of its trading volume [3] - Lingkang Pharmaceutical (603669) with a net inflow of 64.68 million yuan, representing 37.53% of its trading volume [3]

Group 1 - The market is experiencing significant divergence, with the Shanghai Composite Index slightly up by 0.13% while the ChiNext Index down by 0.47%, indicating a mixed performance among individual stocks [2][4] - Certain sectors like agriculture, oil, and petrochemicals are leading the gains, while the technology sector is seeing an overall decline, highlighting the ongoing sector rotation [2][4] - The A-share market often reacts to news with a time lag, where positive news can coincide with peak stock prices, contrasting with foreign markets that trade based on known information [4][10] Group 2 - Historical data suggests that the white liquor sector faced a crisis in May 2025, with a significant drop of over 6% in 20 trading days following a liquor restriction announcement, indicating that market warnings were present before the event [5][9] - The "institutional inventory" data shows that institutional investors had already exited before the downturn, suggesting that the decline was not unexpected but rather a predictable outcome [9][12] - The case of Nuotai Biotech, which saw a 25% increase after being designated as ST (special treatment), illustrates that institutional trading patterns can lead to unexpected stock performance, where negative news can serve as a tool for market manipulation [10][12] Group 3 - The analysis of market trends reveals that sectors experiencing gains are often backed by prior institutional investments, while those declining show low institutional inventory, indicating a lack of sustained interest from institutional investors [12][14] - The importance of observing real-time capital flows and utilizing quantitative tools is emphasized for investors to navigate the current market effectively [14]

Financial Performance - The company reported a total revenue of 1.048 billion yuan for the first half of 2025, representing a year-on-year increase of 26.07% [1] - The net profit attributable to shareholders reached 310 million yuan, up 36.49% year-on-year [1] - The gross margin improved to 69.57%, an increase of 3.35% compared to the previous year, while the net margin rose to 28.84%, up 3.48% [1] Quarterly Analysis - In Q2 2025, the total revenue was 483 million yuan, showing a slight increase of 1.47% year-on-year [1] - The net profit for Q2 was 157 million yuan, which marked a decline of 2.12% year-on-year [1] Key Financial Ratios - The company’s total expenses (selling, administrative, and financial) amounted to 240 million yuan, accounting for 22.93% of revenue, an increase of 15.93% year-on-year [1] - Earnings per share (EPS) increased to 0.99 yuan, reflecting a growth of 30.26% year-on-year [1] Asset and Liability Changes - Cash and cash equivalents increased by 21.88% to 677 million yuan, primarily due to the redemption of structured deposits [3] - Interest-bearing liabilities surged by 72.94% to 2.026 billion yuan, indicating a significant increase in debt [1][3] - Accounts receivable rose by 25.75% to 613 million yuan, attributed to increased sales revenue [3] Investment and Development - The company has seen a 78.5% increase in construction in progress, driven by multiple ongoing projects [3] - The intangible assets grew by 42.39% due to the capitalization of certain pharmaceutical products [5] Cash Flow Analysis - The net cash flow from operating activities increased by 59.33%, attributed to higher cash collections from customers [26] - The net cash flow from investing activities decreased by 8.52%, reflecting increased purchases of fixed assets [26] Market Position and Business Model - The company’s return on invested capital (ROIC) was reported at 11.52%, indicating average capital returns [28] - The business model relies heavily on capital expenditures, necessitating careful evaluation of the profitability of these investments [28] Fund Holdings - The largest fund holding in the company is the "招商蓝筹精选股票A," which has increased its position, currently holding 2.7458 million shares [28]

Core Viewpoint - ST诺泰 (688076.SH) reported strong financial performance in the first half of 2025, driven by high demand for peptide raw materials, with revenue increasing by 26.07% to 1.048 billion yuan and net profit rising by 36.49% to 310 million yuan [2] Group 1: Financial Performance - The company achieved a revenue of 1.048 billion yuan, reflecting a year-on-year growth of 26.07% [2] - The net profit attributable to shareholders reached 310 million yuan, marking a 36.49% increase compared to the previous year [2] - The non-recurring net profit was reported at 306 million yuan, up by 33.49% year-on-year [2] Group 2: Market Expansion and Strategic Collaborations - The company has expanded its market presence in traditional markets like Europe and the U.S., while also covering emerging markets in Latin America and Asia-Pacific [3] - Strategic collaborations with leading generic drug companies have been established for projects involving semaglutide and teriparatide raw materials [3] - The company is building a second growth curve by leveraging platform strategies in emerging business sectors like oligonucleotides and conjugates [3] Group 3: Capacity Expansion - The company’s Lianyungang factory has launched a fourth-generation large-scale peptide production workshop, achieving an annual production capacity of 5 tons [4] - The newly established Jian’de factory has added 220,000 liters of GMP-grade product capacity with two multifunctional synthesis workshops and two D-grade clean areas [4] - The company is expected to complete the construction of its oligonucleotide commercial production workshop by October 2025, with an annual capacity of 1,000 kg for oligonucleotides and 200 kg for PEG-conjugated cyclic peptides [4] Group 4: R&D and Technological Advancements - The company is actively investing in cutting-edge technologies and has formed strategic partnerships to enhance its R&D capabilities [5] - A strategic cooperation agreement was signed with a leading company in biological manufacturing to advance synthetic biology technology [5] - The company aims to integrate AI technology into drug development, optimizing operations and building a comprehensive AI-driven pharmaceutical system [6] Group 5: Workforce and Innovation - The number of R&D personnel has reached 459, a 42% increase year-on-year, with 47% holding master's or doctoral degrees [6] - The company is focusing on interdisciplinary advantages to enhance its competitive edge in technology R&D and innovation [6] - Investments in various advanced technologies, including synthetic biology and AI-driven chemical processes, are expected to support the company's long-term sustainable development [6]